W R Grace

69.99

0.0000

Volume:- -

Turnover:- -

Market Cap:4.64B

PE:60.38

High:69.99

Open:69.99

Low:69.99

Close:69.99

52wk High:70.00

52wk Low:38.70

Shares:66.27M

Float Shares:55.80M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.93

Dividend Rate:1.33%

EPS(TTM):1.16

EPS(LYR):-0.0271

ROE:16.68%

ROA:4.17%

PB:13.38

PE(LYR):-2,578.00

Loading ...

Overview Company News Filings

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

GlobeNewswire

·

Feb 11, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRA\",,,,,undefined,":{"symbol":"GRA","market":"US","secType":"STK","nameCN":"W R Grace","latestPrice":69.99,"timestamp":1678482000000,"preClose":69.99,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":55804989,"shares":66270051,"eps":1.159245,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-19 07:44:58 EDT","open":69.99,"high":69.99,"low":69.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.159245,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779197400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":69.99,"dividendRate":0.013288,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRA\",,,,,undefined,":{"symbol":"GRA","floatShares":55804989,"roa":"4.17%","roe":"16.68%","lyrEps":-0.027149,"shares":66270051,"dividePrice":0.93,"high":69.99,"amplitude":0,"preClose":69.99,"low":69.99,"week52Low":38.7,"pbRate":"13.38","week52High":70,"institutionHeld":0.8016,"latestPrice":69.99,"eps":1.159245,"divideRate":0.013288,"volume":0,"delay":0,"ttmEps":1.159245,"open":69.99,"prevYearClose":54.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-09-22","symbol":"GRA","reason":null,"defaultRemindTime":1632317400000,"announcedDate":"2021-09-13","type":"delisting","dateTimestamp":1632283200000},{"market":"US","date":"2021-08-02","symbol":"GRA","fiscalQuarterEnding":"2021/06","expectedEps":0.98,"name":null,"time":"","type":"earning","dateTimestamp":1627876800000,"reportTimeType":"","actualEps":1.01},{"market":"US","date":"2021-05-06","symbol":"GRA","fiscalQuarterEnding":"2021/03","expectedEps":0.73,"name":null,"time":"","type":"earning","dateTimestamp":1620273600000,"reportTimeType":"","actualEps":0.73},{"market":"US","date":"2021-03-01","symbol":"GRA","amount":0.33,"name":"格雷斯事务所","recordDate":"2021-03-23","payableDate":"2021-03-02","currency":"USD","type":"dividend","dateTimestamp":1614574800000},{"market":"US","date":"2021-02-09","symbol":"GRA","fiscalQuarterEnding":"2020/12","expectedEps":0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1612846800000,"reportTimeType":"pre","actualEps":0.88}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRA\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-27","recordDate":"2017-03-01","paymentDate":"2017-03-23","value":0.21,"currency":"USD"},{"executeDate":"2017-05-15","recordDate":"2017-05-17","paymentDate":"2017-06-08","value":0.21,"currency":"USD"},{"executeDate":"2017-08-15","recordDate":"2017-08-17","paymentDate":"2017-09-07","value":0.21,"currency":"USD"},{"executeDate":"2017-11-14","recordDate":"2017-11-15","paymentDate":"2017-12-07","value":0.21,"currency":"USD"},{"executeDate":"2018-02-28","recordDate":"2018-03-01","paymentDate":"2018-03-22","value":0.24,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRA","date":"2021-09-20","current":60.375503,"percent":0.752019,"low":-2530.315104,"twenty":25.305698,"median":36.068849,"eighty":68.005433,"high":700.822833,"avg":-14.140343,"sd":533.040565,"marketCap":4637578168},"quantilePoints":[{"date":"2021-05-21","current":184.481087,"twenty":23.186974,"median":34.789407,"eighty":63.80012,"marketCap":4538234737},{"date":"2021-05-28","current":184.454155,"twenty":23.375134,"median":34.811754,"eighty":64.516829,"marketCap":4537572220},{"date":"2021-06-04","current":185.160085,"twenty":23.464381,"median":34.848014,"eighty":65.486713,"marketCap":4554938093},{"date":"2021-06-11","current":185.025423,"twenty":23.642075,"median":34.870151,"eighty":66.045188,"marketCap":4551625411},{"date":"2021-06-18","current":185.052356,"twenty":23.89115,"median":34.900189,"eighty":66.35421,"marketCap":4552287947},{"date":"2021-06-25","current":186.102718,"twenty":24.042041,"median":34.955374,"eighty":66.588769,"marketCap":4578126869},{"date":"2021-07-02","current":186.614433,"twenty":24.25683,"median":35.007575,"eighty":67.193783,"marketCap":4590715062},{"date":"2021-07-09","current":186.901028,"twenty":24.464214,"median":35.042563,"eighty":67.435789,"marketCap":4597765282},{"date":"2021-07-16","current":187.170415,"twenty":24.654772,"median":35.09476,"eighty":67.500944,"marketCap":4604392214},{"date":"2021-07-23","current":187.547558,"twenty":24.920537,"median":35.164166,"eighty":67.752258,"marketCap":4613669919},{"date":"2021-07-30","current":187.385925,"twenty":25.195668,"median":35.263076,"eighty":67.929108,"marketCap":4609693760},{"date":"2021-08-06","current":59.496663,"twenty":25.311322,"median":35.366516,"eighty":67.994263,"marketCap":4599092057},{"date":"2021-08-13","current":59.565888,"twenty":25.311322,"median":35.432862,"eighty":67.994263,"marketCap":4604443143},{"date":"2021-08-20","current":59.497303,"twenty":25.311322,"median":35.610347,"eighty":67.994263,"marketCap":4599141539},{"date":"2021-08-27","current":59.634473,"twenty":25.305698,"median":35.72867,"eighty":68.005433,"marketCap":4609744747},{"date":"2021-09-03","current":59.720204,"twenty":25.305698,"median":35.832203,"eighty":68.005433,"marketCap":4616371752},{"date":"2021-09-10","current":59.943104,"twenty":25.305698,"median":35.937826,"eighty":68.005433,"marketCap":4633601965},{"date":"2021-09-17","current":59.968824,"twenty":25.305698,"median":36.034338,"eighty":68.005433,"marketCap":4635590067},{"date":"2021-09-20","current":59.994543,"twenty":25.305698,"median":36.068849,"eighty":68.005433,"marketCap":4637578168}],"updateTime":1779188211138},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510809033","title":"Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510809033","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510809033?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270760,"startTime":"0","endTime":"0","summary":"LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3023967/0/en/Lipella-Pharmaceuticals-Reports-Positive-Topline-Phase-2a-Results-for-LP-310-in-the-Treatment-of-Oral-Lichen-Planus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRA","IGA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}